Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 29Surveys and Questionnaires 25Blood Specimen Collection 17Gene Expression Profiling 15Flow Cytometry 14Polymerase Chain Reaction 13Amplified Fragment Length Polymorphism Analysis 13Microarray Analysis 11Observation 10Interviews as Topic 10Psychiatric Rehabilitation 9Lenalidomide 9Immunohistochemistry 9Cytogenetic Analysis 9obinutuzumab 8Watchful Waiting 8Therapeutics 8ibrutinib 7Drug Therapy 7Cyclophosphamide 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6fludarabine 5In Situ Hybridization, Fluorescence 5Immunologic Techniques 5Data Collection 5Biopsy 5zanubrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Glycopeptides × Lymphoid × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡